Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Johnson Controls International PLC (JCI) vs Eli Lilly And Co (LLY) Price & Performance

Johnson Controls International PLCTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Johnson Controls International PLC vs Eli Lilly And Co — how do they compare? Johnson Controls International PLC trades at $154.35 (market cap $93.74B), while Eli Lilly And Co trades at $1,219.75 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 11.5× Johnson Controls International PLC's market cap, and Johnson Controls International PLC pays the higher dividend (1.03%). Which is the better fit depends on your goals.

JCILLY
Market Cap
$93.74B$1.08T
Sector
IndustrialsHealth
52-Week High
$154.76$1.24K
52-Week Low
$103.52$639.43
Enterprise Value
$102.58B$1.13T
Dividend Yield
1.03%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Johnson Controls International PLC

Johnson Controls International (JCI) trades at $154.06, up 2.23% on the day, with a bullish technical signal from moving averages and strong recent earnings beats. The company reported robust Q3 2026 results with organic sales growth of 10% and raised its full-year guidance, driven by demand for data-center thermal management systems. Valuation ratios are elevated, with a P/E of 43.59 and P/S of 3.82, reflecting growth expectations. The stock is near its pivot point of $154, with immediate resistance at $155.

The outlook for JCI is positive, supported by strong operational momentum and strategic positioning in energy-efficient building solutions. Key opportunities include expanding AI-related cooling demand and consistent earnings outperformance. Risks involve high valuation multiples, increasing debt-to-asset ratios, and potential macroeconomic pressures on construction markets. Analyst consensus remains strongly bullish with a $168.25 price target, though investors should monitor execution on growth initiatives.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Johnson Controls International PLC

Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.

Read more on JCI

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY